Antibody Information

General Information of This Antibody
Antibody ID
ANI0YZUIO
Antibody Name
Ramucirumab
Brand Name
CYRAMZA
Organization
Dyax Corp.; Eli Lilly & Co.; ImClone LLC
Indication
Gastric cancer; Non-small cell lung cancer; Colorectal cancer; Hepatocellular carcinoma
Approval Date
Apr, 2014
Synonyms
1121B; IMC-1121B; LY3009806; CYRAMZA
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-kappa
Antigen Name
Vascular endothelial growth factor receptor 2 (KDR)
  Antigen Info 
ChEMBI ID
CHEMBL1743062
PDB ID
3s34 , 3s36 , 3s37
DrugBank ID
DB05578
Drug Central ID
4917
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYY
ADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSSASTK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Varible Domain
EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYY
ADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSS
    Click to Show/Hide
Heavy Chain Constant Domain 1
ASTKGPSVLPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV
    Click to Show/Hide
Heavy Chain Constant Domain 2
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
    Click to Show/Hide
Heavy Chain Constant Domain 3
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Hinge Region
EPKSCDKTHTCPPCP
    Click to Show/Hide
Heavy Chain CDR 1
GFTFSSYS
    Click to Show/Hide
Heavy Chain CDR 2
ISSSSSYI
    Click to Show/Hide
Heavy Chain CDR 3
ARVTDAFDI
    Click to Show/Hide
Light Chain Sequence
DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPS
RFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIKGTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPS
RFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIK
    Click to Show/Hide
Light Chain Constant Domain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain CDR 1
QGIDNW
    Click to Show/Hide
Light Chain CDR 2
DAS
    Click to Show/Hide
Light Chain CDR 3
QQAKAFPPT
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
2-DG/aV-siCPT1C [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
1.10 ug/mL
Positive VEGFR2 expression (VEGFR2 +++/++)
Method Description
The Cell Counting Kit-8 (CCK8) method was used to detect the effect of nanocapsules on cell viability. The cultured U87 and HA1800 cells were placed in a 96-well plate at a density of 5 x 103 cells/well. After 24 h of culture, PBS, 2-DG/aV-siCPT1C NC were added.
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
References
Ref 1 Cascade-Responsive 2-DG Nanocapsules Encapsulate aV-siCPT1C Conjugates to Inhibit Glioblastoma through Multiple Inhibition of Energy Metabolism. ACS Appl Mater Interfaces. 2023 Mar 1;15(8):10356-10370. doi: 10.1021/acsami.2c19285. Epub 2023 Feb 14.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.